Literature DB >> 10725292

Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

R E Law1, S Goetze, X P Xi, S Jackson, Y Kawano, L Demer, M C Fishbein, W P Meehan, W A Hsueh.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor-gamma (PPARgamma) is activated by fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZDs). The TZD troglitazone (TRO) inhibits vascular smooth muscle cell (VSMC) proliferation and migration in vitro and in postinjury intimal hyperplasia. METHODS AND
RESULTS: Rat and human VSMCs express mRNA and nuclear receptors for PPARgamma1. Three PPARgamma ligands, the TZDs TRO and rosiglitazone and the prostanoid 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), all inhibited VSMC proliferation and migration. PPARgamma is upregulated in rat neointima at 7 days and 14 days after balloon injury and is also present in early human atheroma and precursor lesions.
CONCLUSIONS: Pharmacological activation of PPARgamma expressed in VSMCs inhibits their proliferation and migration, potentially limiting restenosis and atherosclerosis. These receptors are upregulated during vascular injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725292     DOI: 10.1161/01.cir.101.11.1311

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  97 in total

1.  Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry.

Authors:  Yingfeng Wang; Wenju Lu; Kai Yang; Yan Wang; Jie Zhang; Jing Jia; Xin Yun; Lichun Tian; Yuqin Chen; Qian Jiang; Bo Zhang; Xiuqing Chen; Jian Wang
Journal:  J Mol Med (Berl)       Date:  2014-11-14       Impact factor: 4.599

Review 2.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

3.  Regulation of vascular smooth muscle cell proliferation by nuclear orphan receptor Nur77.

Authors:  Liyue Wang; Fan Gong; Xiaoyan Dong; Wei Zhou; Qiutang Zeng
Journal:  Mol Cell Biochem       Date:  2010-04-22       Impact factor: 3.396

4.  Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype.

Authors:  Min Ding; Ana Catarina Carrão; Robert J Wagner; Yi Xie; Yu Jin; Eva M Rzucidlo; Jun Yu; Wei Li; George Tellides; John Hwa; Tamar R Aprahamian; Kathleen A Martin
Journal:  J Mol Cell Cardiol       Date:  2011-09-17       Impact factor: 5.000

5.  Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling.

Authors:  Dane Meredith; Manikandan Panchatcharam; Sumitra Miriyala; Yau-Sheng Tsai; Andrew J Morris; Nobuyo Maeda; George A Stouffer; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-29       Impact factor: 8.311

6.  Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

Authors:  Ningning Wang; J David Symons; Hui Zhang; Zhanjun Jia; Frank J Gonzalez; Tianxin Yang
Journal:  Toxicol Pathol       Date:  2008-12-15       Impact factor: 1.902

Review 7.  Drugs for cardiovascular risk reduction in the diabetic patient.

Authors:  D S Bell
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

8.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Authors:  Andrew C Li; Christoph J Binder; Alejandra Gutierrez; Kathleen K Brown; Christine R Plotkin; Jennifer W Pattison; Annabel F Valledor; Roger A Davis; Timothy M Willson; Joseph L Witztum; Wulf Palinski; Christopher K Glass
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells.

Authors:  Wiebke Wolfsgruber; Susanne Feil; Sabine Brummer; Oliver Kuppinger; Franz Hofmann; Robert Feil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

Review 10.  Impact of thiazolidinedione therapy on atherogenesis.

Authors:  Jeroen P H van Wijk; Ton J Rabelink
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.